Open AccessClinical and economic analysis of effectiveness of Nivolumab (Opdivo®) use as second-line monotherapy in adult patients with advanced renal cell carcinoma after previous systemic therapy
Author(s) -
M. Yu. Frolov,
I. Krysanov,
V. Krysanova
Publication year - 2017
Publication title -
onkourologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 4
eISSN - 1996-1812
pISSN - 1726-9776
DOI - 10.17650/1726-9776-2017-13-1-53-66
Subject(s) - medicine , nivolumab , renal cell carcinoma , everolimus , cost effectiveness analysis , oncology , combination therapy , cost effectiveness , cancer , immunotherapy , risk analysis (engineering)